<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE316nnn/GSE316421/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316421</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen</name><description>Vaccines capable of eliciting broadly neutralising antibodies (bnAbs)are a major goal for pandemic preparedness. A persistent challengeacross vaccine fields is how to deliberately recruit the rare B cellclones that recognise conserved epitopes shared across diverse viralvariants. BnAbs have been known to frequently emerge throughextensive somatic hypermutation during affinity maturation, here wedescribe an alternative, structure-driven mechanism for bnAbselection. We designed an mRNA vaccine in which two antigenicallydistinct SARS-CoV-2 variant’s (Omicron and Delta; O-Δ) receptorbinding domains (RBDs) are physically fused on a singlepolypeptide. This design is predicted to favour B cell antigenreceptors capable of engaging conserved epitopes on both RBDs withenhanced avidity. A matched non-divergent tandem RBD (Delta-Delta;Δ-Δ) served as a control. The divergent (O-Δ) immunogen was robustlyexpressed and retained high-affinity ACE2 binding. In mice,immunisation elicited potent antibody responses and increased thefrequency of antigen-specific cross-reactive B cells, recognisingDelta, Omicron, and the 2002 pandemic strain SARS-CoV RBDs. Usingmulticolour RBD tetramers and single-cell B cell receptor sequencing,we show that breadth arises via two distinct pathways. The divergentvaccine preferentially enriches clonally distinct cross-reactive Bcells (not present within non-cross-reactive B cell pools) with lowlevels of somatic hypermutation (SHM), consistent with selection ofgermline-biased precursors. In contrast, the matched control vaccineyields cross-reactivity primarily within existing clonal lineages(clonal overlap between cross- reactive and non-cross-reactive cells)and at higher mutational burdens, consistent with affinity-maturation-driven acquisition of breadth. Together, these findingsdemonstrate that antigen structure can bias B cell selection towardscross-reactive specificities without requiring extensive SHM. Thiswork establishes a simple, modular antigen-design principle in whichjuxtaposing appropriately divergent antigens on a single scaffoldpromotes the enrichment of bnAb-prone B cells, providing a scalablestrategy for vaccine development against rapidly evolving pathogens.</description><dates><publication>2026/08/13</publication></dates><accession>GSE316421</accession><cross_references><GSM>GSM9453026</GSM><GSM>GSM9453025</GSM><GPL>32159</GPL><GSE>316421</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>